SETD2 and lung adenocarcinoma: With the largest cohort to date, we demonstrate that SETD2-mutated lung adenocarcinoma presents at significantly earlier stages, has a unique molecular profile compared to non-mutated tumors, and trends towards improved RFS in early-stage tumors.